Briefs: Concord Biotech and Neuland Laboratories
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
More than 10,000 scientific publications containing EUDRAGIT
The company is confident of addressing the concern raised by the USFDA
ANVISA issues CGMP to Concord Biotech’s Unit I
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Subscribe To Our Newsletter & Stay Updated